Año: 2012
Journal Impact Factor (JIF): 4.5780
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | SCIE | 11/70 | Q1 | T1 | D2 |
| MICROBIOLOGY | SCIE | 22/116 | Q1 | T1 | D2 |
Año: 2017
Journal Citation Indicator (JCI): 1,340
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | 13/111 | Q1 | T1 | D2 | 88,74 |
| MICROBIOLOGY | 20/145 | Q1 | T1 | D2 | 86,55 |
Año:
2012
CiteScore:
7,200
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 22/230 | Q1 | T1 | D1 |
| Microbiology (medical) | 8/96 | Q1 | T1 | D1 |
SJR año:
2012
Factor de Impacto:
1,868
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Medicine (miscellaneous) | 181/2882 | Q1 | T1 | D1 |
| Microbiology (medical) | 11/119 | Q1 | T1 | D1 |
| Infectious Diseases | 29/288 | Q1 | T1 | D2 |
| Agencia | Código de Proyecto |
|---|---|
| Abbott | - |
| Andalucian Health Service | - |
| BH | - |
| BMS | - |
| Boehringerm Ingelheim | - |
| Bristol Myers Squibb | - |
| Bristol-Myers Squibb | - |
| FIS (Spanish Health Research Fund) | - |
| Gilead | - |
| Gilead Sciences | - |
| Glaxo Smithkline | - |
| GlaxoSmith-Kline | - |
| Janssen | - |
| Janssen-Cilag | - |
| Junta de Andalucia | SAS 111 212; SA 047 |
| Merck | - |
| Merck Sharp Dohme | - |
| Ministerio de Sanidad | EC11-001 |
| MSD | - |
| Pfizer | - |
| Red Tematica Cooperativa de Investigacion en SIDA | ISCIIIRETIC0006/0016 |
| Roche | - |
| Spanish AIDS Research Network (RETICS-RIS) | - |
| ViiF | - |
| ViiV Healthcare | - |
| ViiV Healthcare laboratories | - |
| # | Autor |
|---|---|
| 1 | Monge, S |
| 2 | Guillot, V |
| 3 | Alvarez, M |
| 4 | Pena, A |
| 5 | Viciana, P |
| 6 | Garcia-Bujalance, S |
| 7 | Elias, MJP |
| 8 | Iribarren, JA |
| 9 | Gutierrez, F |
| 10 | Casado, MI |
| 11 | |
| # | Autoría grupal |
| 1 | López Cortés, Luis Fernando (CoRIS) |